Champlain Investment Partners LLC Has Increased Integra Lifesciences Holdings (IART) Stake by $4.40 Million; Market Valuation Rose

Investors sentiment increased to 1.32 in Q2 2019. Its up 0.05, from 1.27 in 2019Q1. It is positive, as 20 investors sold IART shares while 65 reduced holdings. 39 funds opened positions while 73 raised stakes. 68.86 million shares or 0.56% less from 69.24 million shares in 2019Q1 were reported. Moreover, Mesirow Financial Invest Mgmt has 1.13% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Public Employees Retirement Of Ohio stated it has 0.02% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Fort Limited Partnership invested in 0.01% or 548 shares. State Teachers Retirement Sys reported 74,458 shares. Segall Bryant Hamill Limited Liability invested in 140,642 shares. Pure Financial Inc accumulated 10,781 shares or 0.11% of the stock. Atlanta Com L L C stated it has 685,995 shares. Nordea Inv Mngmt has 0.01% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 89,838 shares. Tiverton Asset has invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Brown Advisory Inc holds 0.23% or 1.45M shares. Piedmont Invest Advsr Inc invested in 6,840 shares or 0.02% of the stock. The New York-based Goldman Sachs has invested 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Retail Bank Of Montreal Can reported 17,350 shares or 0% of all its holdings. State Treasurer State Of Michigan reported 21,000 shares. Ameritas Inv Ptnrs Incorporated reported 20,862 shares or 0.05% of all its holdings.

Champlain Investment Partners Llc increased its stake in Integra Lifesciences Holdings (IART) by 1.98% based on its latest 2019Q2 regulatory filing with the SEC. Champlain Investment Partners Llc bought 88,031 shares as the company’s stock rose 24.59% . The institutional investor held 4.54 million shares of the laboratory analytical instruments company at the end of 2019Q2, valued at $228.96 million, up from 4.45 million at the end of the previous reported quarter. Champlain Investment Partners Llc who had been investing in Integra Lifesciences Holdings for a number of months, seems to be bullish on the $5.20 billion market cap company. The stock increased 2.89% or $1.71 during the last trading session, reaching $60.84. About 315,967 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 3.56% since October 12, 2018 and is uptrending. It has outperformed by 3.56% the S&P500.

Champlain Investment Partners Llc, which manages about $6.04 billion and $8.47 billion US Long portfolio, decreased its stake in Steris Plc by 181,720 shares to 1.08M shares, valued at $95.85M in 2019Q2, according to the filing. It also reduced its holding in Insulet Corporation (NASDAQ:PODD) by 228,535 shares in the quarter, leaving it with 1.09 million shares, and cut its stake in Align Technology Inc. (NASDAQ:ALGN).

More notable recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: Globenewswire.com which released: “Integra LifeSciences to Host Second Quarter 2019 Earnings Results Conference Call on July 24, 2019 – GlobeNewswire” on July 10, 2019, also Seekingalpha.com with their article: “Stocks To Watch: Spotlight On FOMC, Slack And Paris Air Show – Seeking Alpha” published on June 15, 2019, Globenewswire.com published: “Integra LifeSciences launches SurgiMend® MP Collagen Matrix for Hernia Repair – GlobeNewswire” on May 12, 2017. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: Pharma Earnings Pick Up Pace – Benzinga” published on July 20, 2019 as well as Globenewswire.com‘s news article titled: “Integra LifeSciences Introduces New Codman Specialty Surgical Products at AANS 2019 – GlobeNewswire” with publication date: April 11, 2019.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.